Abstract
The androgen receptor (AR) plays a central role in the initiation and growth of prostate cancer. Androgen deprivation therapy (ADT) has been a gold standard for advanced prostate cancer for decades. Unfortunately, suppressive effects of ADT do not last long and hormone-refractory prostate cancer develops within several years. In spite of extensive research on mechanisms of hormone-independent growth of prostate cancer, there are few effective treatment options for recurrent tumors and most patients die from the disease in a short period of time. Accumulating evidence suggests that the AR signaling system remains intact and activated despite low levels of androgens in hormone-resistant prostate cancer. Currently, modifications to the AR via mutations, amplification and phosphorylation have been proposed as underlying mechanisms of hormone-resistance of prostate cancer cells. In addition, changes in AR cofactors are implicated in ligand-independent activation of AR signaling. Thus, the development of novel and more effective treatment modalities targeting the AR and AR-related molecules may provide better management of androgen-independent prostate cancer. Although recent patents on the AR related to prostate cancer are focused on antiandrogens, future trend will be shifted to agents or methods suppressing molecules or pathways that activate AR signaling in low androgen environments.
Keywords: Prostate, neoplasms, androgen, receptor, amplification, phosphorylation, mutation
Recent Patents on Anti-Cancer Drug Discovery
Title: The Androgen Receptor as Putative Therapeutic Target in Hormone-Refractory Prostate Cancer
Volume: 2 Issue: 3
Author(s): Yukio Kageyama, Nobuhiko Hyochi, Kazunori Kihara and Hiroshi Sugiyama
Affiliation:
Keywords: Prostate, neoplasms, androgen, receptor, amplification, phosphorylation, mutation
Abstract: The androgen receptor (AR) plays a central role in the initiation and growth of prostate cancer. Androgen deprivation therapy (ADT) has been a gold standard for advanced prostate cancer for decades. Unfortunately, suppressive effects of ADT do not last long and hormone-refractory prostate cancer develops within several years. In spite of extensive research on mechanisms of hormone-independent growth of prostate cancer, there are few effective treatment options for recurrent tumors and most patients die from the disease in a short period of time. Accumulating evidence suggests that the AR signaling system remains intact and activated despite low levels of androgens in hormone-resistant prostate cancer. Currently, modifications to the AR via mutations, amplification and phosphorylation have been proposed as underlying mechanisms of hormone-resistance of prostate cancer cells. In addition, changes in AR cofactors are implicated in ligand-independent activation of AR signaling. Thus, the development of novel and more effective treatment modalities targeting the AR and AR-related molecules may provide better management of androgen-independent prostate cancer. Although recent patents on the AR related to prostate cancer are focused on antiandrogens, future trend will be shifted to agents or methods suppressing molecules or pathways that activate AR signaling in low androgen environments.
Export Options
About this article
Cite this article as:
Kageyama Yukio, Hyochi Nobuhiko, Kihara Kazunori and Sugiyama Hiroshi, The Androgen Receptor as Putative Therapeutic Target in Hormone-Refractory Prostate Cancer, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (3) . https://dx.doi.org/10.2174/157489207782497172
DOI https://dx.doi.org/10.2174/157489207782497172 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Marine Collagen as a Source of Bioactive Molecules: A Review
The Natural Products Journal Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Effect of two Antiandrogens as Protectors of Prostate and Brain in a Huntington`s Animal Model
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy for Prostate Cancer: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets G Protein β γ Subunits as Targets for Small Molecule Therapeutic Development
Combinatorial Chemistry & High Throughput Screening Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Cellular Functions of RNA-Binding Motif Protein 3 (RBM3): Clues in Hypothermia, Cancer Biology and Apoptosis
Protein & Peptide Letters Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets Fulvestrant - A Novel Endocrine Therapy for Breast Cancer
Current Medicinal Chemistry Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design Analysis of Differential Gene Expression Based on Bayesian Estimation of Variance
Current Bioinformatics Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology Preface: Studies on Understanding and Anti-Tumor Agents of Reproductive Cancer Cells
Current Pharmaceutical Biotechnology CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry Curcumin Entrapped Into Lipid Nanosystems Inhibits Neuroblastoma Cancer Cell Growth and Activates Hsp70 Protein
Current Nanoscience